CRISPR Therapeutics Jumps on Takeover Buzz
CRISPR Therapeutics stock surges 6% amid fresh speculation that Vertex Pharmaceuticals may pursue an acquisition.
/ 3 items
#VRTX↓
Morgan Stanley Shifts Outlook on Vertex and Regeneron
Morgan Stanley upgrades Vertex Pharmaceuticals on promising kidney pipeline progress and downgrades Regeneron due to balanced risk/reward and valuation concerns.
Vertex Faces Pain Drug Setbacks Amidst Q2 Earnings Beat
Vertex Pharmaceuticals' stock fell after its pain drug VX-993 failed a trial. Despite this, Q2 earnings exceeded estimates, driven by cystic fibrosis drugs. Journavx also faces FDA limitations.